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Background: Dementia includes a group of neurodegenerative disorders characterized by progressive loss of
cognitive function and a decrease in the ability to perform activities of daily living. Systematic reviews of diagnostic
test accuracy (DTA) focus on how well the index test detects patients with the disease in terms of figures such as
sensitivity and specificity. Although DTA reviews about dementia are essential, at present there is no information
about their quantity and quality.
Methods: We searched for DTA reviews in MEDLINE (1966–2013), EMBASE (1980–2013), The Cochrane Library (from
its inception until December 2013) and the Database of Abstracts of Reviews of Effects (DARE). Two reviewers
independently assessed the methodological quality of the reviews using the AMSTAR measurement tool, and the
quality of the reporting using the PRISMA checklist. We describe the main characteristics of these reviews, including
basic characteristics, type of dementia, and diagnostic test evaluated, and we summarize the AMSTAR and PRISMA
scores.
Results: We selected 24 DTA systematic reviews. Only 10 reviews (41.6%), assessed the bias of included studies and
few (33%) used this information to report the review results or to develop their conclusions Only one review (4%)
reported all methodological items suggested by the PRISMA tool. Assessing methodology quality by means of the
AMSTAR tool, we found that six DTA reviews (25%) pooled primary data with the aid of methods that are used for
intervention reviews, such as Mantel-Haenszel and separate random-effects models (25%), while five reviews (20.8%)
assessed publication bias by means of funnel plots and/or Egger’s Test.
Conclusions: Our assessment of these DTA reviews reveals that their quality, both in terms of methodology and
reporting, is far from optimal. Assessing the quality of diagnostic evidence is fundamental to determining the
validity of the operating characteristics of the index test and its usefulness in specific settings. The development of
high quality DTA systematic reviews about dementia continues to be a challenge.
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Population ageing is generating a considerable increase in
chronic and neurodegenerative diseases, as well as severe
consequences for global public health [1,2]. Dementia in-
cludes a group of neurodegenerative disorders characte-
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article, unless otherwise stated.the ability to perform activities of daily living, sometimes
accompanied by neuropsychiatric symptoms [3]. Criteria
for dementia diagnosis include a deficit in one or more
cognitive domains that is severe enough to impair func-
tional activities, and is progressive over a period of at least
six months and not attributable to any other brain disease
[4,5]. The presence of cognitive impairment, a fundamental
part of the dementia profile, could be detected through a
combination of history, clinical examination, and objective
cognitive assessment such as a brief mental assessment or
comprehensive neuropsychological testing [6,7]. At present,ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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dementia diagnosis criteria, such as amyloid-β protein ac-
cumulation, neuronal injury, synaptic dysfunction, and
neuronal degeneration [8-10].
Systematic reviews of diagnostic test accuracy (DTA)
focus on how well an index test detects patients with the
disease in terms of figures such as sensitivity and specifi-
city. DTA reviews present summarized information to
consumers (such as clinicians, stakeholders, guideline
developers and patients) about which test should be
used over another as the initial step in a diagnostic path-
way or as an add-on element to confirm the presence of
the target disease. Although the methodology for per-
forming DTA reviews is constantly evolving, organiza-
tions such as the Cochrane Collaboration have published
methodological guidance with basic requirements to de-
velop these kinds of reviews [11].
Recently, we evaluated the quality of clinical practice
guidelines for diagnosing dementia and found a wide
variety in terms of quality of evidence as well as the
strength of the recommendations provided [12]. Although
DTA reviews are an essential part of any clinical guide-
lines, at present there is no information about the quantity
and quality of dementia DTA reviews. This information
could help clinicians and stakeholders provide adequate
management and appropriate care for these patients, in
line with the rise in dementia and its expected burden on
health systems.
The objective of this study was to evaluate the quality
(in terms of rigor in conduct and reporting) of DTA sys-
tematic reviews related to diagnostic tools for Alzheimer’s
disease dementia (ADD) and other dementias. These tools
included brief cognitive tests, biomarkers, and neuro-
psychological assessment, and they were assessed by
means of standardized tools, as well as by describing the
tests evaluated and their main characteristics.
Methods
We produced a protocol for the review (available from the
authors on request) detailing the proposed review methods.
We searched in MEDLINE (1966–2013), EMBASE (1980–
2013), The Cochrane Library (from its inception until De-
cember 2013) and the Database of Abstracts of Reviews of
Effects (DARE), by means of a predesigned search strategy
adapted to each database (Additional file 1), in order to
identify diagnostic systematic reviews focused on the test
accuracy of diagnostic tools for dementia, ADD or other
dementias (e.g. vascular dementia, frontotemporal demen-
tia, Lewy bodies, and Parkinson dementia). We checked the
reference lists of the selected studies for additional refer-
ences, and excluded congress abstracts and references with
insufficient information.
Two reviewers independently assessed the eligibility of
the results and extracted data from the selected studies.In this overview we included systematic reviews of diag-
nostic studies that focused on the accuracy of tests for
dementia. Only reviews that used a systematic approach,
included adult patients aged over 50 suspected of having
dementia, and estimated the accuracy of the assessed
test (i.e. providing sensitivity and specificity figures) were
considered. We used a predefined data extraction form
to extract descriptive information including year of pub-
lication, type of studies included, and clinical reference
standard, and whether a checklist was used to evaluate
the methodological quality of primary studies (such as
the Quality Assessment of Diagnostic Accuracy Studies,
QUADAS [13,14]).
After this was done, two reviewers independently
assessed the methodological quality of the selected re-
views using the Assessment of Multiple Systematic Re-
views (AMSTAR) measurement tool [15], tailored to the
characteristics of DTA systematic reviews (Additional
file 1). They also assessed the quality of the reporting
using the Preferred Reporting Items for Systematic re-
views and Meta-Analyses (PRISMA) checklist [16]. We
resolved disagreements through discussion. In this art-
icle we describe the main characteristics of the selected
reviews, including basic characteristics (e.g. reference
standard used and diagnostic bias reported). We also de-
scribe the type of dementia and index test evaluated, as
well as AMSTAR and PRISMA scores by item.
Results
We retrieved a total of 549 citations after excluding du-
plicates and initially selected a total of 76 references for
full review. We excluded 52 articles because they did not
provide diagnostic accuracy information, presented a
narrative overview about dementia, or did not have
enough information to evaluate their quality (i.e. con-
gress abstracts) (Additional file 1). Finally, we selected
24 DTA systematic reviews [17-40], with a median sam-
ple size of 2,190 patients (range from 160 to 26,019)
(Figure 1 and Additional file 1).
Ten reviews (41.6%) focused on mild cognitive impair-
ment (MCI), an early stage of dementia, either for detec-
tion or conversion to full dementia, while nine reviews
(37.5%) focused on ADD, and eight on dementia in gen-
eral. Eight out of 24 DTA reviews (33%) included more
than one subtype of dementia. Seven studies (29%) had
less than 1,000 patients, and a similar number did not
report the total number of patients derived from primary
studies, while nine (37.5%) of the reviews included less
than 10 studies (Additional file 1).
The reviews selected included mostly cross-sectional
and cohort studies, with a median of 19.5 primary stud-
ies included (range from two to 233 primary studies).
The index tests most frequently evaluated were cognitive
tests (nine DTA reviews), followed by PET/SPECT and
Search strategies results: 606
549 references from search strategies
76 citations selected by title and abstract
24 Diagnostic accuracy 
systematic reviews to be 
included.
52 studies excluded due to:
Only abstract/conference proceeding: 8
No dx accuracy assessment:21
No systematic review:23
57 duplicates
Figure 1 Flowchart of the systematic search.
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each). Several reference standards were used to validate
dementia diagnoses, with NINCS-ARDRA and DSM-IV
being the most common (11 and nine reviews, respec-
tively). Four DTA reviews did not indicate the reference
standard used to evaluate the validity of dementia diag-
noses. Table 1 shows the selected reviews by type of de-
mentia and diagnostic tool evaluated.
Only 10 reviews (41.6%) assessed the methodological
quality of primary studies, with QUADAS-I being the
most commonly used tool for assessing risk of bias of pri-
mary studies (six studies, 60%). Patient spectrum and in-
corporation bias were the most frequent biases reported
by review authors. Four reviews assessed the methodo-
logical quality of primary studies by means of the STARD
tool (16%), which is intended to assess reporting quality.
None of the DTA reviews reported results related to in-
conclusive results, adverse events, or the use of resources
related to index tests in an explicit way. Eleven reviews
(45.8%) reported the sources of funding or support to per-
form the DTA review with most of them being govern-
ment sources.
With regards to the PRISMA checklist, all selected re-
views (100%) described the rationale for the review (Item
3), and 20 (83.3%) identified themselves as systematic
reviews (Item 1). Twenty-two reviews (91.6%) reported
the number of studies screened, assessed for eligibility,and included in the review, by means of a flow chart (Item
17) and 21 (87.5%) presented characteristics of studies and
provided citations (Item 18). However, only one study
(4.1%) reported a review protocol (Item 5), four (16.6%)
reported results of additional analysis (Item 23), and five
(20.8%) presented results of risk of bias assessment across
studies as publication bias or selective reporting within
studies (Item 22). Only one review reported all methodo-
logical items suggested by the PRISMA tool (Items 5 to
16) (Figure 2).
With respect to the quality of conduct in terms of the
AMSTAR tool, 21 reviews (87.5%) did not provide a list
of included/excluded studies and 16 (66.6%) did not re-
port duplicate study selection/data extraction (Figure 3).
All reviews reported the characteristics of included stud-
ies (100%). Six DTA reviews (25%) pooled primary data
by means of methods that are used for intervention re-
views such as Mantel-Haenszel and separate random-
effects models, while in seven reviews (29%) it was not
possible to determine which methods were used to com-
bine the numerical results. Five reviews (20.8%) assessed
publication bias by means of funnel plots and/or Egger’s
Test. Fourteen of these DTA reviews (58.3%) reported
possible conflicts of interest. As mentioned above, only
10 reviews (41.6%) assessed the bias of included studies,
and only eight (33%) used this information to report the
review results or reach their conclusions.
Table 1 DTA systematic reviews about dementia by type of dementia and diagnostic tool evaluated
MMSE Other
cognitive tests




ADD Bloudek [19] Bloudek [19] Bloudek [19] Bloudek [19] Bloudek [19]
Dougall [22] Mitchell [28] Matchar [27]
Ferrante [24] Patwardhan [34]
DLB Yeo [40] Van Harten [36] Papathanasiou [33]
Treglia [35]
Yeo [40]
VaD Dougall [22] Van Harten [36] Beynon [18] Yeo [40]
Yeo [40]









MCI Lischka [25] Ehreke [23] Yuan [38] Monge [32] Mitchell [28] Zhang [39] Yuan [38]
Lonie [26] Lischka [25] van Rossum [37] Monge [32]
Mitchell [29] Lonie [26] van Rossum [37]
Abbreviations: Aβ 42 42 aminoacid form of amyloid-β, ADD Alzheimer’s Disease Dementia, CT Computed tomography, DLB Dementia with Lewy Bodies, FDG-PET
PET using 2-Fluro-deoxy D-glucose, FTD Fronto-Temporal Dementia, MCI Mild cognitive Impairment, MMSE Mini-Mental State Examination, MRI Magnetic
Resonance Imaging, PIB-PET 11 C-Pittsburgh Compound B- positron emission tomography, Ptau Phosphorylated Tau, SPECT Single photon emission computed
tomography, Ttau Total Tau, VaD Vascular Dementia.
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Our review of DTA systematic reviews about dementia
shows several areas for improvement. First, we had
to exclude a significant number of reviews focused not on
the accuracy of the test (i.e. sensitivity and specificity
figures), but instead presenting information about the
average differences between case and control groups. In
these reviews, the authors gathered information about
Phase I diagnostic studies, evaluating the differences (for
example, in terms of difference of means) between a group
of subjects with the disease and healthy controls [41].
These studies are essential for an adequate and full assess-
ment of any diagnostic tool, but cannot show if the test
distinguishes between those with and without the target
condition. Authors of future reviews should be careful in
appraising these studies due to the higher risk of bias (for
instance, the wide use of cases and controls design) and
their limitations in decision-making processes.
In relation to the basic characteristics of dementia
DTA systematic reviews, we noticed that a significant
number of reviews were focused on mild cognitive im-
pairment (MCI). Identification of early forms of demen-
tia has become an important topic because some
interventions have been claimed to be effective in slow-
ing or stopping the cognitive decline when they are ad-
ministered in earlier stages of dementia, but thesefindings are still being investigated [42-45]. Similarly, it
is interesting that a significant number of reviews fo-
cused on cognitive tests, which are the first line of detec-
tion for cognitive impairment in dementia. At present it
is unclear which cognitive test should be the instrument
of choice for initial dementia screening in population-
based, primary and secondary settings, due to rising
criticism of the role of traditional tests such as Mini-
Mental State examination (MMSE) [12].
Our assessment of these DTA reviews reveals that
their quality, in terms of both methodology and report-
ing, is far from optimal. We found that more than half
of the included reviews did not provide a quality assess-
ment of the primary studies, and therefore information
of an unknown quality was gathered and even numerical
pooled results were provided. Assessing the quality of
diagnostic evidence is fundamental to determining the
validity of the operating characteristics of the index test,
and its usefulness in specific settings [46]. Four reviews
(16%) did not report the reference standards they used
to evaluate the accuracy of the different tests appraised,
while others reported STARD scores as an evaluation of
methodological quality. Only 13 of the 24 reviews (54%)
described the limitations of the information gathered,
and in only eight cases (33%) was the quality of this in-














































































































































Figure 2 PRISMA items reported by DTA reviews about dementia. Notes: Item 1 = Identify the report as a systematic review; Item 2 = Provide a
structured summary; Item 3 = Describe the rationale of the review; Item 4 = Provide an explicit statement of questions being addressed; Item 5 = Indicate
if a review protocol exists; Item 6 = Specify study characteristics; Item 7 = Describe all information sources in the search and date last searched; Item
8 = Present full electronic search strategy; Item 9 = State the process for selecting studies; Item 10 = Describe method of data extraction; Item 11 = List
and define all variables for which data were sought; Item 12 = Describe methods used for assessing risk of bias of individual studies; Item 13 = State the
principal summary measures; Item 14 = Describe the methods of handling data and combining results; Item 15 = Specify any assessment of risk of bias
that may affect the evidence; Item 16 = Describe methods of additional analyses; Item 17 = Give numbers of studies screened, assessed for eligibility, and
included in the review; Item 18 = For each study, present characteristics for which data were extracted; Item 19 = Present data on risk of bias of each
study; Item 20 = For all outcomes present simple summary data, effect estimates and confidence intervals; Item 21 = Present the main results of the
review; Item 22 = Present results of any assessment of risk of bias across studies; Item 23 = Provide results of additional analyses; Item 24 = Summarize the
main findings; Item 25 = Discuss limitations at study and outcome level and at review-level; Item 26 = Provide a general interpretation of the results and
implications for future research; Item 27 = Describe sources of funding for the systematic review.
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almost complete absence of a priori protocols presenting
pre-specified methodological plans. The importance of
pre-specified protocols has been established in interven-
tion reviews as well as in clinical trials of pharmaco-
logical interventions. Diagnostic tests for dementia, such












No. of DTA sy
Yes No Can´
Figure 3 Results of AMSTAR assessment- DTA systematic reviews abo
selection/data extraction; Item 3 = Comprehensive literature search; Item 4
provided; Item 6 = characteristics of the included studies provided; Item 7 =
8 = scientific quality of the included studies in formulating conclusions; Item
Item 10 = publication bias assessed; Item 11 = conflict of interest stated.technologies that can be affected by conflicts of interest.
The availability of protocols at the beginning of any study
not only ensures rigor in development, but also avoids
conducting unnecessary research [47].
In our study we also identified drawbacks in develop-
ing DTA systematic reviews related to the application
of statistical methods generally used in intervention15 20
stematic reviews
t answer Not applicable
ut dementia. Notes: Item 1 = Priori design; Item 2 = Duplicate study
= inclusion criterion -status of publication; Item 5 = list of studies
scientific quality of the included studies assessed & documented; Item
9 =methods used to combine the findings of studies appropriate;
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for pooling numerical information were assessed, we
identified three reviews that used Der Simonian-Laird
random effects models, instead of methods highly rec-
ommended in these cases such as bivariate models [48].
Some authors have asserted that the use of inadequate
statistical techniques to deal with diagnostic information
could lead to failures in managing the combined results
of sensitivity and specificity [48-51]. Similarly, some re-
views used the I2 statistic to illustrate the heterogeneity
between the analyzed studies. Heterogeneity is a com-
mon issue in accuracy reviews, due to factors such as
threshold used, prevalence of the target condition in the
sample selected, and settings of test evaluation [52], but
at present, there are no defined standards for how diag-
nostic heterogeneity should be measured and managed
in DTA reviews [53].
In the same way, we identified that evaluation of publica-
tion bias remains a problem in dementia DTA reviews. In
our study, 18 reviews (75%) did not provide information
about this bias, but it is unclear if the authors simply omit-
ted this evaluation or if they decided not to assess this
topic due to lack of suitable analysis methods. Three add-
itional cases (12.5%) used funnel-plot figures or statistical
tests (for instance, Egger’s test). While these methods are
highly useful in intervention systematic reviews, several
research studies have shown that their use in the field of
DTA reviews, usually by means of diagnostic odds ratios
(DOR), can generate misleading results [54].
Our study has some limitations. One of these is related
to the tools used to evaluate systematic reviews (such as
PRISMA and AMSTAR), focused mainly on intervention
reviews. In order to correctly use the AMSTAR tool we
developed tailored definitions to adequately reflect the
most accepted methodology of DTA systematic reviews.
However, it is important to encourage discussion about
how current tools and methodologies (for example, over-
view methodology) can be applied or adapted to devel-
oping DTA studies. A second difficulty that we found
was the large number of diagnostic reviews reported
only in abstract form, which had to be excluded because
of the absence of information to allow for a full assess-
ment of their elements. We believe that these “ongoing”
studies reflect the growing interest in the diagnosis of
dementia, as well as the need for comprehensive discus-
sion about dementia diagnosis tools. Finally, our search
strategy was specific and did not include terms related
to MCI. Our findings related to this early stage of de-
mentia might be incidental and not reflect all possible
DTA reviews in this area.
Conclusions
Development of systematic reviews of diagnostic test
accuracy for dementia remains a difficult task. However,an increasing number of health professionals require
information about the quality of diagnostic technologies
due to their role in detecting, staging and monitoring. We
believe that some recent initiatives might help improve
methodology and reporting quality in DTA reviews on
dementia [11,48,55]. In the near future, high quality DTA
reviews could play an important role in helping clinicians,
policy-makers and even patients to make informed deci-
sions for the diagnosis of this prevalent disease.
Additional file
Additional file 1: This file includes the following information: 1. Search
strategy used on MEDLINE. 2. Operational definitions of AMSTAR’s Items
for DTA reviews about dementia. 3. DTA systematic reviews about
dementia- Descriptive information. 4. DTA systematic reviews about
dementia- AMSTAR items. 5. DTA systematic reviews about dementia- PRISMA
items. 6. List of excluded studies.
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